News
Interesting panel on SBIR rules
This report comes from from an interesting panel on the SBIR rule changes at the 2005 Mid-Altlantic BIO, presented by Douglas Duncan (Montgomery County County Executive), Michael Rosenwald (Washington Post biotech reporter), Douglas Doerfler (President & CEO, MaxCyte), Gerald McGarrity (President & CEO, Intronn), Barry Michael (Michael Consulting), Maciek Sasinowski (CEO, INCOGEN), and Mary Woolley (President & CEO, Research! America)
Briefly, recent rule changes disqualify small companies that are more than 50% held by entities that do not qualify as small companies. The impact of this rule is that most venture-backed organizations are no longer eligible for SBIR funding.
Some of the opinions that arose from the discussion are:
From Yali Friedman, Ph.D.,
Full Story: http://biotech.about.com/b/a/213774.htm
MATR Supporters (view all)
Sorry, we couldn't find any posts. Please try a different search.